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Evaluating and Understanding the Reason for an Increase in Nonconformances in the
Laboratory
A. Mukungu 1, Z. Ekeocha 2, S. Byrn 3, K. Clase 4

ABSTRACT
This is a study of nonconformances experienced by a laboratory of a pharmaceutical manufacturing
facility in East Africa. There has been an increase in nonconformances from 216 nonconformances in
2017 to 229 in 2018 and by September 2019, 306 nonconformances were already logged. Increasing
nonconformances result in delayed release of tested materials and many resources are wasted (e.g.
chemicals, man hours and equipment). Analysts become frustrated, which may result in inexhaustive
investigations. Understanding the reason for the increase in nonconformances will enable the facility
to derive effective solutions to the identified causes, hence reducing the number of nonconformances
and improving the productivity and morale of employees. This quantitative, nonexperimental,
longitudinal survey study was intended to evaluate and understand the reason for increasing
nonconformances. Trends of the nonconformances, previous investigations, procedure for
investigation and the training given to analysts have been reviewed. Laboratory incidences were the
most recurring nonconformances; and these were mainly caused by analyst errors. Corrective and
Preventive Actions (CAPAs) were derived by cross functional teams whenever root causes were
identified. Procedure for investigation of nonconformances refers to investigative tools. Identification of
root causes to nonconformances recently became mandatory. Analysts have limited advanced
industrial training on investigation of nonconformances. Another study should be carried out to
understand the cause of analyst errors. The study can be rolled out to other departments at the
manufacturing facility to create similar improvements. Analysts should enroll into advanced courses of
industrial pharmacy to gain advanced industrial skills which they can apply in investigations to find root
causes to nonconformances.
KEYWORD: Regulatory compliance, current Good Manufacturing Practices, Define Measure Analyse
Improve and Control (DMAIC), Failure investigations, Laboratory nonconformances, Quality culture,
Lean manufacturing
Current Good Manufacturing Practices
(CGMPs) refers to the regulations that guide the
design, monitoring, and maintenance of
manufacturing facilities and processes. They
are accepted industry practices outlining the
minimum standards for manufacturing practices
for production of drugs and biologics intended
for human and animal use (FDA, 2018; NDA,
2020; WHO, 2008). The pharmaceutical
regulatory agencies, such as the National Drug
Authority of Uganda (NDA), World Health
Organisation (WHO), and Food and Drug

Authority (FDA), enforce the regulations to
ensure that manufacturing facilities of
pharmaceutical products, medical devices, food
and beverages, and dietary supplements are in
good condition, the equipment is well
maintained and calibrated, and the employees
are well trained and qualified to handle the
manufacturing equipment and processes.
Laboratory nonconformances can come from
three categories. The first category is an out of
specification (OOS) test result; a test result that
falls outside the specification or acceptance

amukungu@purdue.edu; Biotechnology Innovation and Regulatory Science (BIRS) Center; Agricultural and
Biological Engineering, Purdue University
2 zekeocha@purdue.edu; Medical Missionaries of Mary; Biotechnology Innovation and Regulatory Science (BIRS)
Center, Purdue University
3 sbyrn@purdue.edu; Biotechnology Innovation and Regulatory Science (BIRS) Center; Industrial and Physical
Pharmacy, Purdue University
4 kclase@purdue.edu; Biotechnology Innovation and Regulatory Science (BIRS) Center; Agricultural and Biological
Engineering, Purdue University
1

2

criteria established in drug applications, drug
master files and official compendia or approved
company specification. Conformance to
specification means that the drug substance
and drug product, when tested according to the
listed analytical procedures, will meet the
acceptance criteria. Specifications are critical
quality standards that are proposed and justified
by the manufacturer and approved by regulatory
authorities as conditions of approval (Ravi Kiran
et al., 2017). The second category of
nonconformances is an out of trend (OOT) test
result, a test result that does not follow the
expected trend in comparison with either results
obtained among the batch or results of other
batches or atypical observation identified which
is not obvious as per expectations. The third
category of nonconformances ais a laboratory
incidence, an occurrence, other than OOS/OOT
during the performance of a test procedure or
identified during review such as instrument
malfunction, analyst errors, system suitability
failure, laboratory obvious errors, variations of
results among replicate determinations or any
kind of other error.
The problem of nonconformances in the quality
control laboratory was known as early as the
1920s but it was not understood until the 1990s
that lack of statistical and metrological thinking
was the main aspect of the problem (Ravi Kiran
et al., 2017). Regulatory agencies assess the
facilities that manufacture, package, test and
distribute drug products for adherence to the
CGMPs and this assessment is a measure of
their regulatory compliance (Markovitz, 2011).
Critical among the key principles of CGMP is
quality control which includes all measures
taken, including the setting of specifications,
sampling, testing and analytical clearance, to
ensure that raw materials, intermediates,
packaging materials and finished
pharmaceutical products conform with
established specifications or identity, strength,
purity and other characteristics (WHO, 2018).
All regulators are always interested in
understanding a facility`s approach to
investigation of nonconformances with the aim
of identifying how exhaustive the investigations
are in identifying root causes to observed
nonconformances. Regulations require
identification of product defects and the cause

of the defects and implementation of the
corrective actions as part of a quality
management system. Title 21 of the U.S. Code
of Federal Regulations (2019), requires
manufacturers to use appropriate methodology
to detect recurring quality problems and identify
actions needed to correct and prevent
recurrence of nonconformances. However, the
regulations do not state how to do this; they do
not identify good or bad corrective and
preventive action programs, systems or steps.
The responsibility of conducting effective
investigations and identifying appropriate
CAPAs is left to the pharmaceutical industries
(Haleem et al., 2015). There is a general lack of
documented guidance that can be used daily to
ensure compliance (Pathak, 2007). Haleem et
al. (2015), concluded that in general, CAPA
experts recommend that root cause
investigations follow a four-step process:
1. Identify the problem.
2. Evaluate its magnitude, which includes
assessing risk.
3. Investigate and assign responsibility.
4. Analyse and document the root cause of
the problem.
Ravi Kiran et al. (2017), documented a detailed
investigation of a nonconformance that was
observed while testing a finished product in the
laboratory. The investigation follows the
recommended four step process in order to
reach to the root cause of the problem.
Recommendation has been given to the
pharmaceutical industry to go beyond good and
adopt best practices, as is exercised in other
sectors, such as the nuclear and aerospace
operations. Highlighting of errors to facilitate
improvement is among the best practices that
were emphasized (Chalk, 2012).
Failure investigations are carried out with the
principle aim of determining the root cause of a
nonconformance. McElroy (2017) noted that
effective investigation of laboratory
nonconformances to identify root causes is a
mandatory requirement of CGMP. The
investigation should ask whether procedures
were followed and whether there was
appropriate control to prevent distribution of the
defective product. The magnitude of the
investigation should correlate with the
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significance and risk of the nonconformance.
Human error is often incorrectly concluded as
the root cause of the manufacturing defect with
retraining as the corrective action resulting in
recurrence of the nonconformance because
human error is not the true root cause. Human
error is an insufficient root cause because it
does not identify the real problem causing the
defect. Beginning to understand why the human
erred will help us understand the true cause of
the problem. Possible causes of human errors
include: confusing procedure, internal
(personal) distractions, external distractions,
unawareness of existence of the procedure,
procedural updates, intentional misuse or willful
misconduct, inadequate electronic clearance on
automated systems, inadequate paper based
systems, inadequate software-based systems,
employee apathy and, finally, the employee
may actually be unable to perform certain steps
(McElroy, 2017). Although these observations
and recommendations provided were based on
a manufacturing set up, they are also applicable
in a quality control laboratory.
The general expectation in a GMP compliant
facility is that a proper evaluation in terms of
defining, measuring and analysing the problem
eases control and results in sustainable
improvement. Poorly investigated
nonconformances can result in drug application
refusal (do Carmo et al., 2017).
Little research has been done specifically about
nonconformances in the laboratory (Haleem et
al., 2015). Numerous articles exist on
nonconformances in the pharmaceutical
industry and the importance of identifying their
root causes is their underlying observation
(Berardinelli, 2012; Chowdary & George, 2012;
Pathak, 2007; Yu & Kopcha, 2017). The sixsigma principle of Define, Measure, Analyse,
Improve and Control (DMAIC) is a structured
problem-solving method that involves a
sequence of interlinked phases that are aimed
at permanently solving problems. It involves
defining a problem, measuring the magnitude of
the problem, analysing the problem to
understand it better, improving the situation in
which the problem occurred and controlling the
situation so that the problem does not recur and
ensuring that improvement interventions are
maintained (Berardinelli, 2012; Yu & Kopcha,

2017). This principle is generally agreed upon
as an acceptable guidance for problem solving
that is aimed at continuous improvement as
illustrated in Figure 1 which shows the
relationship among the key concepts that
demonstrate continuous improvement, a
prerequisite for regulatory compliance.

Figure 1. Graphic sketch of the key concepts
This figure illustrates the relationships among
key concepts that are pre-requisites for
regulatory compliance
The available literature on nonconformances
can be broadly grouped into four categories.
The first category of studies highlights quality
expectations in the industry in general with
focus on quality culture (Friedli et al., 2018;
Harrison & Schniepp, 2015; Lolas & Uydess,
2013). In reference to Patel et al. (2015), quality
(culture) behavior can be defined as follows:
Behaviors observed at the site or organization
that are associated with a strong quality culture
in areas such as clear communication and
transparency, commitment and engagement,
technical excellence, and standardization of
requirements.
Quality (system) maturity is defined as follows:
objective characteristics of a quality system that
can be observed or verified upon inspection or
internal audit that have a positive relationship
with quality culture behaviors, including formal
programs in preventive maintenance,
environmental health and safety, risk
management, human error prevention, and
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training or continuous improvement. The
Economist Intelligence Unit in 2005,
recommended that pharmaceutical industries
should assess whether root cause analysis is
aimed at identifying the underlying causes of
human errors so that human error prevention
and continuous improvement can be realised
through application of lean manufacturing
principles aimed at waste reduction. A robust
quality culture that supports continuous
improvement has been identified to be key in
impacting operational performance of any
organization (Friedli et al., 2018). A quality
culture that supports continuous retraining of
personnel in areas applicable to their job
descriptions was a key strategy in ensuring
regulatory compliance (Jagun, 2018). An
analyst who is highly trained in a required field
will understand the reason behind each step in
a procedure and will be more willing to follow
that procedure. Furthermore, such highly
trained analysts will base their deep
understanding of the analytical techniques to
proactively identify gaps in the procedures and
hence be able to improve on them in areas
where they are deficient. The leadership of
pharmaceutical companies have to be strategic
and adopt improvement strategies to achieve
regulatory compliance (Jagun, 2018). Decisions
based on data have been shown to have
greater impact and found to be more
sustainable (Torbeck, 2011). The culture of
measurement and data should be integrated
into the daily operations of a pharmaceutical
facility for its own benefit and that of its patients.
This study has generated data that can be used
to understand the causes of the increasing
nonconformances in the laboratory and the data
generated will be able to support management
decisions in improving the performance of the
laboratory. Analysis of this data has revealed
that analyst errors are the leading cause of the
nonconformances in the laboratory therefore
creating the need to further understand the
underlying causes of analyst errors.
Deficiencies in documentation have been
identified as a common area in inspections
done by regulatory authorities (Geyer et al.,
2018). Such deficiencies which could include
poorly written procedures, could result in
analyst errors. Investigations that are not
exhaustive enough will conclude the cause as

analyst error, without identifying the underlying
cause of the poorly written unclear procedure.
The second category of studies highlights the
importance of conducting exhaustive
investigations to identifying the underlying root
causes. Chowdary and George (2012),
concluded that the application of principles that
are aimed at elimination of waste improves the
competitiveness of a facility (p.70). This results
in increased profitability allowing the facility to
invest in more value adding activities including
development of new products. Politis and
Rekkas (2011) argued that due to the growing
scarcity of resources, pharmaceutical facilities
need to adopt lean manufacturing principles in
order to remain competitive. Nonconformances
are wasteful; the resources such as chemicals,
time and analyst man hours that are spent on
investigating nonconformances could be better
utilised in other value adding testing activities
that would result in prompt release of materials
for production.
An investigation will only be useful if it is able to
identify the true root cause of the problem so
that when the CAPA is derived, similar
nonconformances do not recur. Anyakora et al.
(2017) maintained that quality improvement
interventions are cost beneficial to local
manufacturing companies (p.8). Understanding
the cause of increasing nonconformances is
cost beneficial to the facility because it will
result in deriving effective solutions to those
causes which will eventually eliminate
recurrence of the nonconformance. Achieving
excellence is a basic requirement of GMPs.
Several principles contribute to regulatory
excellence of a pharmaceutical industry such as
intentionality, attitude, continuous improvement,
discipline, integrity, sustainability and urgency
(Henson, 2011b). These principles can be
applied to the investigation of nonconformances
in the laboratory to realise benefits of
excellence such as reduced waste,
expenditures, enhanced credibility and
improved employee morale. which results in
things getting done. This study was aimed at
employing these principles of excellence in
order to realise similar benefits in the laboratory
of the manufacturing facility.
The third category of literature regarding
nonconformances, highlights challenges that
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pharmaceutical facilities face as they work to
attain compliance. In a phenomenological study
that involved interviews of top executives of
pharmaceutical industries, Pathak (2007)
demonstrated that “noncompliances can be
connected to lack of time to do the job,
inadequate training, accountability of personnel,
or poor decision making process - or a
combination of the above” (p.14). This was a
general study that involved top management
and excluded employees who execute the daily
operations of the industry. This study of
nonconformances was able to cover that gap by
assessing similar challenges at an operational
level, the laboratory. A lack of vigilance in some
facilities that has been coupled with poorly
defined procedures and low capability to
perform exhaustive investigations results in
such facilities concluding with any possible
cause, such as human error as the cause for
nonconformances. These erroneous
conclusions typically lead to recurrences
(Haigney, 2018). Appropriate vigilance is
reflected by the laboratory`s ability to adopt best
practices that ensure a reduction in defects thus
improving efficiency. Key among these
practices is the six-sigma principle of DMAIC
(Rayser, 2019). Conducting a study to
understand causes of increasing
nonconformances is also part of vigilance in the
facility. As part of this vigilance, the cause of
analyst errors in the laboratory should also be
studied. Henson (2011a) reviewed an FDA
warning letter and highlighted that personnel
qualification can affect regulatory compliance.
Inability of training procedures in
pharmaceutical facilities to effectively assess
the level of understanding that has been
attained by the participants and instead focus
on training techniques that demonstrate to
regulators that training actually occurred can
also result in nonconformances (London &
Gray, 2017). Rooney et al. (2002) analysed
causes of human errors in the healthcare
service and defined performance shaping
factors (PSF) as “anything that affects a
worker`s performance of a task within a system”
(p.30). They categorized them as internal PSF,
external PSF and stressors and gave several
examples of each category. The findings and
recommendations of this study are applicable to
a laboratory in a pharmaceutical facility as

similar systems exist with similar factors,
possibly, that could cause analysts to err. If
these factors are not identified and eliminated,
analysts will continue making similar errors and
the number of nonconformances will continue to
increase. Pluta (2012) concluded that
“operations and compliance must support each
other. Investigations need to be conducted
thoroughly; questions, reporting problems, and
other highlighting of problem situations must be
encouraged and rewarded” (p.5).
The fourth category of literature addressing
nonconformances focusses on the
consequences of noncompliance to regulatory
guidelines. Poorly investigated
nonconformances can result in drug application
refusal (do Carmo et al., 2017). Regulators
have a responsibility of ensuring that the drugs
that are sold to the patients of their country
meet the standard requirements of safety,
identity, strength, purity and quality. If a facility
cannot exhaustively investigate its own failures,
regulators will have concerns about the quality
of its medicines and may deny its drug
applications. If a facility demonstrates its ability
to effectively investigate its nonconformances,
regulators will have confidence and respond
positively to drug applications. This creates a
need to evaluate the cause for the increase in
nonconformances in the laboratory. Having
exhaustive investigations will ensure successful
drug applications by this facility. The regulators
will have confidence in their quality
management systems.
Most studies on continuous improvement in the
pharmaceutical industry have been done in the
manufacturing section with no concern to the
laboratory. There are many improvement
opportunities that can be done in a laboratory
and reduction of incidence of nonconformances
is key among them. A similar approach that has
been used by other studies in manufacturing
areas can be applied in the laboratory. There is
very little literature on how investigation of
nonconformances in a pharmaceutical
laboratory should be conducted to avoid
recurrences. The pharmaceutical facility must
come up with compliant ways of exhaustively
investigating nonconformances which should
include understanding the causes of analyst
errors. Although several articles have been
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written on reduction of human error, very few
address how this can be achieved in a
laboratory. By using investigative tools such as
5-Why analysis, the underlying cause of the
human error can be identified hence effective
and lasting solutions can be derived. Some of
the recommendations that have been proposed
in studies about challenges of noncompliance
have not been implemented in the laboratory of
this manufacturing facility. After identifying
analyst errors as the leading cause of
nonconformances, a robust quality culture
requires that the reason behind the analyst
errors be further investigated.

This study originates from a quality culture that
desires to understand the cause of increasing
nonconformances so that corrective and
preventive measures are put in place that will
result in improvements in the efficiency of
testing and continue to maintain regulatory
compliance. Figure 2 illustrates the origin of the
study from available literature by showing how
the current study is related to the four main
categories of literature that were earlier
described.
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Figure 2. Literature map. This figure illustrates the origin of the study from the available literature
Quantitative research methods can be used to
examine relationships between and among
different variables (Creswell & Creswell, 2018).
A survey design provides a quantitative
description of trends by studying a sample of
that population. The quantitative survey
approach enabled the collection of descriptive
data associated with nonconformances in the
laboratory. The survey design was economical

and had rapid turnaround time in data collection
which was aligned with the short period of time
available to conduct the study. An experimental
design was not adopted because it would be
costly to perform such a study within a
commercial set up. A longitudinal survey was
adopted to study the cause of increasing
nonconformances over the period when the
laboratory consistently recorded increasing
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number of nonconformances. A qualitative
research would not allow an interpretation of the
patterns in the trends of nonconformances that
were being observed in the laboratory over the
review period. Hence a quantitative,
nonexperimental longitudinal survey study
design was suitably adopted to evaluate and
understand the reason for an increase in
nonconformances in the laboratory of this
facility,
Studying the causes of increasing
nonconformances in the laboratory is important
for several reasons. First, very few specific
studies are available about nonconformances in
the laboratory indicating the need to add to the
literature that is available so s to cover this gap.
Secondly, this study identified the causes of
recurring nonconformances in the laboratory, if
these are eliminated, it will help improve the
productivity of the laboratory; effective
corrective and preventive solutions will be
derived to the key causes of nonconformances
that have been identified by the study. The
morale of the analysts will improve as their tests
will result in less nonconformances. Less
resources will be wasted on investigations
hence reducing the cost of scrap. (Qeshmy et
al., 2019) performed a detailed analysis of the
root causes of human errors in an automotive
company and studied ways in which such errors
can be mitigated. A similar study should be
done in a pharmaceutical facility to prove the
feasibility of such applications and make use of
the previous research in the nonpharmaceutical industry (Haleem et al., 2015).
Thirdly, based on the results and
recommendations of the study, management
will be able to proactively allocate resources in
preventing occurrence of nonconformances in
the laboratory. Finally, other facilities both in the
pharmaceutical sector and in other sectors, can
also perform similar studies in order to reduce
the incidence of nonconformances hence
lowering waste and increasing their productivity
and competitiveness.
2. METHODS
This quantitative, nonexperimental longitudinal
survey study was intended to evaluate and
understand the reason for an increase in

nonconformances in the laboratory of the
facility. All other departments at the facility
were out of scope.
During the survey, nonconformances logged in
the laboratory from 2017, 2018 until September
2019 were reviewed to establish the number
logged for each category of nonconformances
i.e. laboratory incidences, OOTs and OOSs.
This enabled understanding of categories with
the greatest contributor to nonconformances.
Trends were analysed to identify the most
common recurring nonconformances in the
laboratory. Recurring nonconformances give an
indication of either inexhaustive investigations,
ineffective solutions or poor implementation of
solutions and hence these would require more
review to ensure that their investigations are
improved upon and detailed root cause analysis
is done to avoid recurrence. Root causes
associated with the nonconformances were
reviewed to identify the most common cause of
the nonconformances and the solutions that
were proposed. Having a repetitive cause
indicates another underlying cause that was not
identified and hence still exists. This persistent
unidentified underlying cause continues to lead
to nonconformances in the laboratory until it is
identified and corrected. The procedure for
investigation of nonconformances was
assessed to establish its comprehensiveness
e.g., use of tools like fishbone diagram, 5-why
analysis, Failure Mode Effect and criticality
Analysis (FMEA) and for compliance to
regulatory guidelines. The extent of the
guidance given in an investigation procedure is
an indication of how exhaustive an investigation
will be. Qualifications and trainings of analysts
including those who investigate
nonconformances were analysed to assess
their understanding of the requirements of the
procedure for investigations as well as
regulatory expectations of handling of
nonconformances.
3. RESULTS AND DISCUSSION
The nonconformances were categorised as
laboratory incidences, Out of Specifications
(OOS) and Out of Trends (OOT). Whoever
observed a nonconformance in the laboratory
was required to report it immediately to the
section head or the quality assurance personnel
in the laboratory. Basing on the magnitude of
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the nonconformance, a cross functional team
composed of a member from the quality
assurance department of the facility, the analyst
who was involved in the nonconformance, the
section head of the analyst as well as the
manager of the quality control laboratory would
meet and then derive a strategy for carrying out
the investigation guided by the investigation
procedure.
Table 1
Category and number of nonconformances
logged in the quality control laboratory over the
review period.
Year
Type of Nonconformance
Laboratory
Incidence

Out of
trend

Out of
Specification

2017

143

16

55

2018

175

14

40

failure of lamp ignition of a High-Performance
Liquid Chromatography [HPLC] machine and
malfunctioning of the detector. A procedural
error is an error which may arise due to
unavailability/inadequacy of written
instruction(s) or failure to implement a method
in case of validation. Other error is any other
incidence occurring because of reasons other
than analyst error, instrument error or
procedural error.

2019

2018

2019

264

14

28

Total

582

44

123

Mean

194

15

41

Laboratory incidences were the most
recurring nonconformances and these were
mainly caused by analyst errors. As shown in
Table 1 above and Figure 3 below, from the
749 nonconformances that were logged in the
period evaluated, 77.70% were laboratory
incidences, 16.42% were OOSs and 5.87%
were OOTs. The causes of the
nonconformances were categorized as
analyst errors, instrument errors, procedural
errors and others. An analyst error was
defined as any human action or lack of action
that leads to exceeding the tolerances of the
condition defined for the normative work of
the analytical/ measurement system with
which the human interacts. It may be
categorised as incorrect preparatory work like
weighing error, dilution error, transcription
error and pipetting error. An instrument error
is an error associated with malfunctioning of
the instrument, equipment or software e.g.

2017

0

■

50

100

Out of Specification

150

■

200

Out of trend

250

■

300

Laboratory Incidence

Figure 3. Category and number of
nonconformances logged. This figure
categorises and quantifies the
nonconformances in the quality control
laboratory over the review period.
From Figure 3 above, the main
nonconformance throughout the review period
is laboratory incidences. As shown in Table 2,
the majority of nonconformances were caused
by analyst errors. Other causes included
instrument error, procedural errors and others
which included any cause that did not fall in the
standardized classification as per the
procedure.
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Table 2
Causes of nonconformances in the quality control laboratory over the review period.
Cause of nonconformance
Year
2017
2018
2019
Total per cause
Mean

Analyst error

Instrument
error

Procedural
error

Cause not
identified

Others

57

36

1

44

21

96

57

5

29

19

133

58

8

42

24

286

151

14

115

64

95

50

5

38

21

The cause could not be identified in some of the
investigations.
The procedure for investigation of
nonconformances gives reference to
investigative tools like fishbone/Ishikawa
diagram and the 5-Why analysis. It had been
recently revised to add a mandatory
requirement to identify root causes to
nonconformances, or at least identify a probable
cause.
The leading two causes of nonconformances
are analyst errors (45.4%) and instrument errors
(24.0%) (see Figure 4). Procedural errors were
the least likely cause of nonconformances
(2.2%). The cause of some nonconformances
was not identified for some cases (10.2%).
Congestion was the main cause for the
category of others. The laboratory was small
and congested hence the analysts had little
working space.
Corrective and Preventive Actions (CAPAs)
were derived by cross functional teams that
composed of a member from the quality
assurance department of the facility, the analyst
who was involved in the nonconformance, the
section head of the analyst who observed the
nonconformance as well as the manager of the
quality control laboratory. Based on the root
causes that were identified during the
investigation, corrective and preventive actions
were derived.

Cause not
identified

Others

Procedural error

Instrument error

Analyst error

0

20

•2017

40

60

• 2018

80

100

• 2019

120

140

.
Figure 4. Causes of nonconformances in the
quality control laboratory. This figure
demonstrates causes of the nonconformances
over the review period.
The analysts, including those responsible for
conducting investigations have been thoroughly
trained on the new procedure. However, they
have no external training outside the company
on investigation of nonconformances. A review
of qualifications and trainings of analysts
revealed that most analysts have bachelor's
degrees in science fields, the entry level
qualification requirement for an analyst in this
facility and none had any advanced industrial
training to enhance their investigation skills.
From the study conducted, the main reason for
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the increase in nonconformances in the
laboratory is analyst errors hence the cause(s)
for the analyst errors need to be identified and
addressed in order to reduce the number of
nonconformances and improve the productivity
of the laboratory. Since this project has been
successful in identifying the main cause of
nonconformances in the laboratory, it can be
rolled out to other departments at the facility.
4. CONCLUSION
The main reason for the increase in
nonconformances in the laboratory is the
increase in analyst errors. In line with the
concept of quality culture that requires detailed
root cause analysis, causes of the analyst
errors are currently being analysed and
congestion within the laboratory has been
identified as a principal cause. A congested
area is likely to have external factors that will
cause distraction to the analysts as they carry
out the analysis. Laboratory expansion to
create more space is currently underway.
Procedural errors are the least cause of
nonconformances. In a few cases, the cause of
the nonconformance could not be identified.
The identified CAPAs were based on the root
causes identified during the investigation. The
investigation procedure has recently been
revised to make it mandatory for investigations
to identify root causes of nonconformances.
5. RECOMMENDATIONS FOR NEXT STEPS.
Investigations of nonconformances should
always find the causes of human errors. When
this is done, effective and long lasting CAPAs
will be derived that will sustainably lower the
incidence of nonconformances in the laboratory.
The procedure for investigation should have a
mandatory requirement to identify root cause of
analyst errors. The qualifications of personnel
have been proven to be a key factor associated
with compliance. Investigators and analysts
should be enrolled in advanced industrial
courses which teach lean manufacturing and
equip students with trending investigation skills
and tools as well as knowledge on how these
can be applied in the industry. Management
should continue using these results to
proactively allocate resources in preventing
occurrence of nonconformances in the
laboratory by training its personnel throughout
the facility and adding advanced qualifications

as part of the recruitment criteria. The study can
be rolled out to other departments to evaluate
and understand the reason for the incidence of
nonconformances in their respective areas. The
causes of human errors in the facility should be
identified to derive sustainable solutions to
them. Other pharmaceutical facilities can
perform similar studies that are rooted in a
quality culture that desires to understand the
cause of increasing nonconformances so that
corrective and preventive measures are put in
place that will result in improvements in the
efficiency of testing and continue to maintain
regulatory compliance. This study is applicable
to any area where nonconformances are
observed and these can manifest as defective
products in such areas.
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